Altimmune, Inc.
NASDAQ:ALTBiotechnology
Healthcare
$1.53 +3.09%
+$0.08 today
- Market cap
- $297.72M
- Beta
- 0.23
- P/E (TTM)
- -3.7
- EPS (TTM)
- -$0.73
52W Low $2.56High $7.73
Volume 4.25M
Average 3.81M
Income Statement
Follow revenue through to earnings.
Revenue
$41,000.00
FY 2025 · Annual
+105.0% YoYOperating Income
-$94.49M
FY 2025 · Annual
Net Income
-$88.09M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.41M | (68K) | 426K | 20K | 41K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 4.41M | (68K) | 426K | 20K | 41K |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 74.54M | 70.54M | 65.8M | 82.23M | 66.43M |
| Selling, General & Admin | 15.41M | 17.13M | 18.14M | 20.97M | 28.1M |
| Operating Expenses | 101.32M | 87.67M | 96.36M | 103.19M | 94.53M |
| Depreciation & Amortization | 551K | 493K | 477K | 238K | 112K |
| EBITDA | (96.53M) | (84.41M) | (87.94M) | (94.81M) | (87.03M) |
| EBITDA Margin | -2189.0% | 124130.9% | -20642.0% | -474060.0% | -212258.5% |
| Operating Income | (96.91M) | (87.74M) | (95.93M) | (103.17M) | (94.49M) |
| Operating Margin | -2197.6% | 129029.4% | -22518.5% | -515860.0% | -230461.0% |
| Interest Income | 203K | 2.87M | 7.35M | 8.07M | 7.54M |
| Interest Expense | 5K | 8K | 35K | 9K | 1.64M |
| Other Income / Expenses | (176K) | 2.83M | 7.48M | 8.11M | 5.72M |
| Income Before Tax | (97.09M) | (84.91M) | (88.45M) | (95.06M) | (88.77M) |
| Pre-Tax Margin | -2201.6% | 124867.6% | -20762.2% | -475295.0% | -216522.0% |
| Income Tax Expense | 0 | (197K) | 0 | 0 | (681K) |
| Net Income | (97.09M) | (84.71M) | (88.45M) | (95.06M) | (88.09M) |
| Net Margin | -2201.6% | 124577.9% | -20762.2% | -475295.0% | -214861.0% |
| EPS (Basic) | (2.35) | (1.81) | (1.66) | (1.34) | (1.00) |
| EPS (Diluted) | (2.35) | (1.81) | (1.66) | (1.34) | (1.00) |
| 41.28M | 46.93M | 53.25M | 71M | 88.1M | |
| 41.28M | 46.93M | 53.25M | 71M | 88.1M |
ALT Earnings Waterfall · TTM
NASDAQ:ALT · Revenue to Net Income
Key Ratios
EPS$-0.93
Gross Margin-74725.0%
Net Margin-232105.8%
P/E Ratio-3.9
P/S Ratio36113.7
Analysis
$36.0K of revenue converted into -$91.1M of net income for the selected period. Gross margin is -74725.0% and net margin is -232105.8%, showing how much revenue survives after costs and taxes. EPS is $-0.93, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 |
How much revenue does ALT generate?
Altimmune, Inc. (ALT) reported $41,000.00 of revenue in fiscal 2025.
Is ALT profitable?
Altimmune, Inc. (ALT) reported -$88.09M of net income, with a net margin of -214861.0%.
Continue the stock analysis
Jump to another research area for this company.